<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057106</url>
  </required_header>
  <id_info>
    <org_study_id>BR34</org_study_id>
    <nct_id>NCT03057106</nct_id>
  </id_info>
  <brief_title>Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC</brief_title>
  <official_title>A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Cancer Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Durvalumab is a new type of drug for many kinds of cancer. It is considered &quot;immunotherapy&quot;&#xD;
      and not &quot;chemotherapy&quot;. Laboratory tests show that it works by allowing the immune system to&#xD;
      detect cancer and reactivate the immune response. This may help to slow down the growth of&#xD;
      cancer or may cause cancer cells to die. Durvalumab has been shown to shrink tumours in&#xD;
      animals and has been studied in more than 5000 people and seems promising.&#xD;
&#xD;
      Tremelimumab is a new type of drug for various types of cancers. It works in a similar way to&#xD;
      durvalumab and may improve the effect of durvalumab. Tremelimumab may also help slow the&#xD;
      growth of the cancer cells or may cause cancer cells to die. It has been shown to shrink&#xD;
      tumours in animals and has been studied in over 1200 people and seems promising.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combinations of durvalumab and tremelimumab have also been studied. While the combination has&#xD;
      been studied in over 200 people, it is not clear if it can offer better results when it is&#xD;
      combined with chemotherapy.&#xD;
&#xD;
      Recently, immunotherapies that target the PD-1/PD-L1 axis have shown promise in treating&#xD;
      patients with non-small cell lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>33 months</time_frame>
    <description>time from randomization to the date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival using RECIST 1.1</measure>
    <time_frame>33 months</time_frame>
    <description>time from randomization to the date of the first documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate using RECIST 1.1 and iRECIST</measure>
    <time_frame>33 months</time_frame>
    <description>proportion of patients with a documented complete response, partial response (CR + PR) based on iRECIST criteria. The primary estimate of ORR will be based on all patients randomized, and compared using Cochran- Mantel-Haeszel test stratified by stratification factors at randomization between the study new treatment and the standard control arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Severity of Adverse Events</measure>
    <time_frame>33 months</time_frame>
    <description>using the NCI Common Terminology Criteria for Adverse Events Version 4.0. A Fisher's exact test will be used to compare adverse events between the study new treatment and the standard control arms if required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness of Durvalumab and Tremelimumab concurrently with combination chemotherapy</measure>
    <time_frame>33 months</time_frame>
    <description>The mean overall cost per patient for each of the two study treatment arms will be calculated to determine the addition cost per life-year gained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate the expression of correlative markers with outcomes and response</measure>
    <time_frame>33 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platinum based chemotherapy + Durvalumab + Tremelimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)&#xD;
Followed by:&#xD;
Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>MEDI4736</description>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
    <arm_group_label>Platinum based chemotherapy + Durvalumab + Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Tremelimumab</description>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
    <arm_group_label>Platinum based chemotherapy + Durvalumab + Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum-Based Drug</intervention_name>
    <description>Pemetrexed, cisplatin, carboplatin or gemcitibine</description>
    <arm_group_label>Platinum based chemotherapy + Durvalumab + Tremelimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically and/or cytologically confirmed diagnosis of squamous&#xD;
             or non-squamous, non-small cell carcinoma of the lung. Patients with poorly&#xD;
             differentiated tumours will only be eligible if NSCLC is confirmed by&#xD;
             immunohistochemistry markers (TTF1/P63 or P40/CK5). Patients with known sensitizing&#xD;
             EGFR mutations or known ALK-fusion are not eligible.&#xD;
&#xD;
          -  Patients must have stage IV disease according to the 8th TNM version staging.&#xD;
&#xD;
          -  Patients must have an adequate histopathology specimen and must consent to release&#xD;
             this specimen for protocol required testing. This is a mandatory component of the&#xD;
             study.&#xD;
&#xD;
          -  Patient must consent to provision of samples of blood in order that the specific&#xD;
             correlative marker assays proscribed may be conducted.&#xD;
&#xD;
          -  All patients must have measurable disease as defined by RECIST 1.1 All radiology&#xD;
             studies must be performed within 28 days prior to randomization (within 35 days if&#xD;
             negative).&#xD;
&#xD;
        The criteria for defining measurable disease are as follows:&#xD;
&#xD;
          -  CT scan (with slice thickness of 5 mm) ≥ 10 mm --&gt; longest diameter&#xD;
&#xD;
          -  Physical exam (using calipers) ≥ 10 mm&#xD;
&#xD;
          -  Lymph nodes by CT scan ≥ 15 mm --&gt; measured in short axis&#xD;
&#xD;
        Measurable lesions must be outside a previous radiotherapy field if they are the sole site&#xD;
        of disease, unless disease progression has been documented.&#xD;
&#xD;
          -  Patients must be 18 years of age or older.&#xD;
&#xD;
          -  ECOG performance status of 0 or 1.&#xD;
&#xD;
          -  Absolute neutrophils ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x UNL (upper limit of normal)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 x UNL (if liver metastases are present, ≤5 x UNL) Creatinine &lt; 1.25&#xD;
             UNL or Creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Cytotoxic Chemotherapy: Patients may not have received prior cytotoxic chemotherapy&#xD;
             for advanced/metastatic disease.&#xD;
&#xD;
          -  Adjuvant Chemotherapy: Patients may have had prior adjuvant therapy for completely&#xD;
             resected disease, providing it has been completed at least 12 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Patients treated with concurrent chemotherapy/radiation regimens for unresectable&#xD;
             locally advanced Stage III disease will be eligible providing it has been completed at&#xD;
             least 12 months prior to randomization.&#xD;
&#xD;
          -  Other Systemic Therapy: Patients may not have received prior EGFR or alk inhibitors.&#xD;
             Patients may not have received prior treatment with immune-based therapy, including&#xD;
             durvalumab and tremelimumab vaccines or oncolytic viral therapy. Patients must have&#xD;
             recovered from any reversible treatment related toxicities prior to randomization.&#xD;
&#xD;
          -  Prior external beam radiation is permitted provided a minimum of 14 days (2 weeks)&#xD;
             have elapsed between the last dose of radiation and date of randomization. Concurrent&#xD;
             radiotherapy is not permitted.&#xD;
&#xD;
        Patients must have recovered from any acute toxic effects from radiation prior to&#xD;
        randomization.&#xD;
&#xD;
          -  Patients must have recovered from any acute toxic effects from radiation prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Surgery: Previous surgery is permitted provided that wound healing has occurred and at&#xD;
             least 14 days have elapsed (major surgery) prior to randomization.&#xD;
&#xD;
          -  Patient must be able (i.e. sufficiently fluent) and willing to complete the quality of&#xD;
             life and health economics questionnaires.&#xD;
&#xD;
          -  Patient consent must be appropriately obtained in accordance with applicable local and&#xD;
             regulatory requirements.&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow-up. All randomized patients must&#xD;
             be followed and treated at participating centres.&#xD;
&#xD;
          -  In accordance with CCTG policy, protocol treatment is to begin within 2 working days&#xD;
             of patient randomization.&#xD;
&#xD;
          -  Female patients of childbearing potential who are sexually active with a&#xD;
             non-sterilized male partner must use at least one highly effective method of&#xD;
             contraception while on study and for 6 months after the last dose of durvalumab and&#xD;
             tremelimumab or for 3 months after the last dose of durvalumab alone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of other malignancies, except: adequately treated non-melanoma&#xD;
             skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours&#xD;
             curatively treated with no evidence of disease for ≥ 3 years. Patients with a history&#xD;
             of other malignancies detected at an early stage and whom the investigator believes&#xD;
             have been curatively treated and are at low risk of recurrence MAY be eligible.&#xD;
             Contact CCTG to discuss eligibility prior to enrolling.&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease (e.g. colitis or Crohn's disease), diverticulitis with the&#xD;
             exception of diverticulosis, celiac disease or other serious gastrointestinal chronic&#xD;
             conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis&#xD;
             syndrome, or Wegener syndrome (granulomatosis with polyangiitis), rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc., within the past 3 years prior to the start of&#xD;
             treatment. The following are exceptions to this criterion:&#xD;
&#xD;
               -  Patients with alopecia.&#xD;
&#xD;
               -  Patients with Grave's disease, vitiligo or psoriasis not requiring systemic&#xD;
                  treatment (within the last 2 years).&#xD;
&#xD;
               -  Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on&#xD;
                  hormone replacement.&#xD;
&#xD;
          -  History of primary immunodeficiency, history of allogenic organ transplant that&#xD;
             requires therapeutic immunosuppression and the use of immunosuppressive agents within&#xD;
             28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated&#xD;
             toxicity from other immune therapy or grade ≥ 3 infusion reaction.&#xD;
&#xD;
          -  Live attenuated vaccination administered within 30 days prior to randomization&#xD;
&#xD;
          -  History of hypersensitivity to durvalumab or tremelimumab or any excipient. Patients&#xD;
             who have received other treatment or other antibodies must not have had intolerable&#xD;
             toxicity or required steroids to manage toxicity.&#xD;
&#xD;
          -  Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec&#xD;
             in screening ECG measured using standard institutional method or history of familial&#xD;
             long QT syndrome.&#xD;
&#xD;
          -  Patients who have untreated and/or uncontrolled cardiovascular conditions and/or have&#xD;
             symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial&#xD;
             infarction within the previous year or cardiac ventricular arrhythmias requiring&#xD;
             medication, history of 2nd or 3rd degree atrioventricular conduction defects).&#xD;
             Patients with a significant cardiac history, even if now controlled, should have a&#xD;
             LVEF ≥ 45%. (Note: patients with uncomplicated controlled hypertension do not require&#xD;
             LVEF measurement in the absence of other significant cardiac history)&#xD;
&#xD;
          -  Concurrent treatment with other investigational drugs or anti-cancer therapy&#xD;
&#xD;
          -  Patients with untreated brain or meningeal metastases are not eligible. Patients with&#xD;
             treated CNS disease who have radiologic AND clinical evidence of stable brain&#xD;
             metastases, with no evidence of cavitation or hemorrhage in the brain lesion, are&#xD;
             eligible providing that they are asymptomatic and do not require corticosteroids (must&#xD;
             have discontinued steroids at least 1 week prior to randomization).&#xD;
&#xD;
          -  Pregnant or Lactating Women: Women of childbearing potential must have a pregnancy&#xD;
             test (urine or serum) proven negative within 14 days prior to randomization. If urine&#xD;
             test is positive, pregnancy testing may then include an ultrasound to rule-out&#xD;
             pregnancy if a false-positive is suspected. For example, when beta-human chorionic&#xD;
             gonadotropin is high and partner is vasectomized, it may be associated with tumour&#xD;
             production of hCG, as seen with some cancers. Patient will be considered eligible if&#xD;
             an ultrasound is negative for pregnancy. Men and women of child-bearing potential must&#xD;
             agree to use adequate contraception.&#xD;
&#xD;
          -  Patients with serious illnesses or medical conditions which would not permit the&#xD;
             patient to be managed according to the protocol (including corticosteroid&#xD;
             administration), or would put the patient at risk. This includes but is not limited&#xD;
             to:&#xD;
&#xD;
               -  Contraindications to the use of pemetrexed, gemcitabine, cisplatin and/or&#xD;
                  carboplatin (consult product monograph);&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorder which would impair the&#xD;
                  ability to obtain consent or limit compliance with study requirements;&#xD;
&#xD;
               -  Active infection requiring systemic therapy; (including any patient known to have&#xD;
                  active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) or&#xD;
                  tuberculosis);&#xD;
&#xD;
               -  Active peptic ulcer disease or gastritis;&#xD;
&#xD;
               -  Known pneumonitis or pulmonary fibrosis with clinically significant impairment of&#xD;
                  pulmonary function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Leighl</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Toronto, ON Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Campbelltown Hospital</name>
      <address>
        <city>Campbelltown</city>
        <state>New South Wales</state>
        <zip>2560</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coffs Habour Health Campus - NCCI</name>
      <address>
        <city>Coffs Harbour</city>
        <state>New South Wales</state>
        <zip>2450</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hospital, Cancer Care Centre</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Cancer Therapy Centre, Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Research Institute South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toowoomba Hospital</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Health Services</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epworth HealthCare - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Victoria</state>
        <zip>3121</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John of God Hospital Subiaco</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Victoria Park</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Health Network</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <zip>E3B 5N5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vitalite Health Network - Dr. Leon Richard</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Health Authority B, Zone 2</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Memorial Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 3G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stronach Regional Health Centre at Southlake</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6B 0A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2S 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Garron Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cite-de-la-Sante</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM-Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Hopital l'Enfant-Jesus (HEJ)</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Institute of Cardiology and</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 11, 2021</submitted>
    <returned>June 4, 2021</returned>
    <submitted>September 13, 2021</submitted>
    <submission_canceled>September 13, 2021</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

